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ADC                               Adenocarcinoma 
cDNA                             Complementary deoxyribonucleic acid 
CFH                              Complement factor H  
CFHL                             CFH-like protein  
CFHR                             CFH-related protein 
DNA                             Deoxyribonucleic acid 
FISH                               Fluorescence in situ hybridization 
GAPDH                          Glyceraldehyde-3-phosphate dehydrogenase 
IHC                               Immunohistochemistry 
LCLC                           Large cell lung cancer 
MAC                             Membrane attack complex  
mRNA                           Message ribonucleic acid 
NSCLC                           Non-small cell lung cancer 
PBS                               Phosphate-buffered saline 
PCR                                Polymerase chain reaction 
PET                                 Positron emission tomography 
RT-PCR                          Reverse transcriptase polymerase chain reaction 
SCC                              Squamous cell carcinoma 
SCLC                          Small cell lung cancer 
TMA                               Tissue microarray 
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Human complement factor H (CFH), a central complement control protein, is a member of the 
regulators of complement activation family. Recent studies suggested that CFH may play a 
key role in resistance of complement mediated lysis in various cancer cells. In this study, we 
investigated the role of CFH in human lung cancer. 
Methods 
Expression of CFH in lung cancer cells was analyzed by RT-PCR, western blotting, and 
immunofluorescence. Binding of CFH to lung cancer cells was detected by flow cytometry. In 
primary lung tumors, the protein expression of CFH was evaluated by IHC on tissue 
microarray.  
Results 
We found, mRNA expression of CFH was detected in six out of ten NSCLC cell lines, but not 
in SCLC cell lines. Consistence with the western blotting result, immunofluorescence analysis 
demonstrated CFH protein expression in three NSCLC cell lines, and the immunoreaction was 
mainly associated with cell cytoplasm and membrane. In primary lung tumors, 54 out of 101 
samples exhibited high expression of CFH, and high expression was significantly correlated 
with lung adenocarcinoma (p=0.009). Also, in ADC of lung, Kaplan-Meier survival analysis 
showed a tendency that CFH-positive tumors had worse prognosis in comparison to CFH-
negative tumors (p=0.082). Additionally, shorter survival time of patients with ADC (less than 
20 months) was associated with higher protein expression of CFH (p=0.033).  
Conclusion 
Our data showed that non-small cell lung cancer cells expressed and secreted CFH. CFH 














Der humane Komplement Faktor H (CFH), ein zentraler Regulator der Komplementkaskade 
gehört zur Familie der Komplement-Aktivatoren. Neuere Studien führen zu der Annahme, 
dass CFH eine wichtige Rolle bei der Verhinderung der Komplement-vermittelte Lyse in 
verschiedenen Krebszellen spielen kann. In dieser Studie untersuchten wir die Rolle von CFH 
im menschlichen Lungenkrebs. 
Methoden 
Die Expression von CFH durch Lungenkrebszellen wurde mittels RT-PCR, Western Blot und 
Immunfluoreszenz analysiert. Die Bindung von CFH an Lungenkrebs-Zellen wurde mittels 
Durchflusszytometrie nachgewiesen. An Hand primärer Lungentumore wurde die 
Proteinexpression von CFH immunhistochemisch an Gewebe-Mikroarrays untersucht. 
Ergebnisse 
Die Expression von CFH-mRNA war in sechs von zehn NSCLC-Zelllinien nachweisbar, nicht 
jedoch in SCLC-Zellinien. Im Einklang mit den Resultaten des Western-Blots belegte die 
Immunfluoreszenzanalytik CFH-Proteinexpression in drei NSCLC-Zelllinien, insbesondere 
zytoplasmatisch und membranassoziiert. Im primären Lungentumorgewebe zeigte sich in 54 
von 101 Fällen eine hohe CFH-Expression, hohe Expressionsraten korrelierten signifikant mit 
dem Auftreten des Adenokarzinomsubtyps (p = 0.009). In der Kaplan-Meier-Analyse zeigte 
sich für das ADC ebenfalls die Tendenz einer Korrelation von CFH-Positivität und schlechter 
klinischer Prognose (p = 0.082). Des Weiteren ist eine kürzere Überlebenszeit von Patienten 
mit ADC (weniger als 20 Monate) mit stärkerer CFH-Färbung (p = 0.033) assoziiert. 
Schlussfolgerungen 
Unsere Daten belegen, dass nicht-kleinzellige Lungenkarzinomzellen CFH exprimieren und 
sezernieren. CFH könnte ein neuer diagnostischer Marker für das menschliche 











1. Classification of lung cancer 
Lung cancer is the leading cause of cancer-related death worldwide (Jemal et al, 2008), and 
only 15% of all lung cancer patients are alive 5 years or more after diagnosis. Common 
symptoms of lung cancer include cough, dyspnoea, weight loss, and chest pain. Symptomatic 
patients are more likely to have obstructive pulmonary disease. 
Lung cancers are classified into two main categories: small-cell lung cancer (SCLC), 
which accounts for approximately 20% of cases, and non-small cell lung cancer (NSCLC), 
which accounts for the other 80%. NSCLC includes squamous cell carcinoma (≈25%), 
adenocarcinoma (≈40%) and large cell carcinoma (≈15%). Squamous cell carcinomas (SCCs) 
arise preferentially from bronchi near the hilus with potential involvement of trachea and 
derive from stem cells of a dysplastic multilayer epithelium that underwent squamous 
metaplasia. Most cases of SCCs are associated with smoking. Well-differentiated squamous 
cell lung carcinomas often grow more slowly than other cancer types (Komaki et al, 2000). 
Adenocarcinomas (ADCs) tend to be located in the periphery of the lung and originate 
preferentially from precursor cells of the mono- or bilayer surface epithelium of the lung 
periphery. Among people who have never smoked ("never-smokers"), ADC is the most 
common form of lung cancer (Subramanian et al, 2007). A subtype of ADC, the 
bronchioloalveolar carcinoma, is more common in female never-smokers, and may have 
different responses to treatment (Raz et al, 2006). Large cell lung carcinoma (LCLC) is a 
heterogeneous group of undifferentiated malignant neoplasm originating from transformed 
epithelial cells in the lung. The newest revisions of the World Health Organization histological 
typing of lung cancer schema includes several variants of large cell carcinoma, such as (a) 
basaloid, (b) clear cell, (c) lymphoepithelioma-like, (d) rhabdoid phenotype, and (e) large cell 
neuroendocrine carcinoma (Brambilla et al, 2001). 
 
2. Biomarkers 
2.1 Cancer biomarkers 
Cancer biomarkers are evaluated for establishing disease predisposition, early detection, 
cancer staging, therapy selection, identifying whether or not a cancer is metastatic, therapy 
monitoring, assessing prognosis, and advances in the adjuvant setting. 
There are several distinct types of biomarkers based on different areas: genetics, 
epigenetics, proteomics, metabolomics, imaging technology, and general physical techniques 
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(Sung and Cho, 2008). Genetics based cancer biomarkers utilize DNA arrays, polymerase 
chain reaction (PCR), reverse transcriptase polymerase chain reaction (RT-PCR), DNA 
sequencing, and fluorescence in situ hybridization (FISH) to detect the genetic alterations 
occurring in the cancerous state. Epigenetic modification usually occurs in CpG islands of the 
gene regulatory regions which results in gene silencing. These alterations can evade the cells 
from their normal cell cycle control and may result in cancer cells formation (Baylin and 
Chen, 2005; Belinsky, 2004). Protein techniques include mass spectrometry (MS), ELISA, 
and immunohistochemistry (IHC), which are utilized to discover novel cancer biomarkers, 
and the biomarkers are later validated in clinical trials. Metabolomics is concerned with the 
study of low molecular weight molecules or metabolites such as amino acids, peptides, lipids, 
and carbohydrates. Imaging techniques such as positron emission tomography (PET), 
Computed Tomographic (CT) scans and Magnetic Resonance Imaging (MRI) are still major 
tools of cancer diagnosis and have the distinct ability to localize the cancer that molecular 
based biomarkers cannot do (Sung and Cho, 2008). 
 
2.2 Lung cancer and its biomarkers 
In patients with suspected lung cancer, a clear and definite diagnosis is essential for the 
treatment strategy (Pio et al, 2010). Late diagnosis is a fundamental obstacle to improving 
lung cancer outcomes (Carney, 2002; Chute et al, 1999). Therefore, early detection of lung 
cancer is obviously the only way to improve the overall survival. Some diagnostic tools 
including CT scans, bronchoscopy, and sputum analysis are routinely used at clinics, but none 
of them turns out to be effective in early diagnosis of lung cancer. There were 512948 
publications from ‘Pubmed’ associated with biomarkers, and 14123 publications were 
associated with lung cancer biomarkers till the end of 2010. Only p63 and CK5/6 are widely 
used as diagnostic markers for SCC of lung, while thyroid transcription factor-1 (TTF-1) 
together with CK7 is considered as a marker for lung ADC. In some cases, even in 
combination with these markers, SCC and ADC still could not be distinguished from each 
other. Given the fact that early detection of lung cancer at stage IA can raise the 5-year 
survival rate from the overall 15% to 80% (Mulshine, 2005), reliable biomarkers for early 
diagnosis and survival prediction are increasingly in demand (Minna and Mangelsdorf, 1997; 
Hirsch et al, 2002). 
 
3. Complement system and regulation of complement activity 
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The complement system is an integral part of the innate immune system. It consists of a 
number of small proteins found in the blood, generally synthesized by the liver, and normally 
circulating as inactive precursors (pro-proteins). There are three biochemical pathways that 
activate the complement system: the classical pathway, the alternative pathway, and the lectin 
pathway. When the complement system is stimulated by one of several triggers, proteases in 
the system cleave specific proteins to release cytokines and initiate an amplifying cascade of 
further cleavage. The result of the activation cascade is massive amplification of the response 
and activation of the cell-killing membrane receptors. The complement system can be 
extremely effective in destroying pathogens, but can be equally damaging to self-tissue. 
Complement regulation occurs predominantly at two steps within the complement cascade, 
the level of the convertase enzymes and of the membrane attack complex (MAC) (Liszewski 
et al, 1996) (Fig. 1). 
 
 
Fig.1 A schematic representation demonstrating that the complement regulatory proteins act 
either at the level of the C3/C5 convertase enzymes or within the terminal complement 
pathway. Membrane-bound factors are encircled whilst soluble regulatory proteins are boxed 
(Turnberg and Botto, 2003). 
 
4. Complement factor H (CFH) 
4.1 The CFH gene family and CFH structure 
CFH is the best characterized protein of the CFH gene family, members of which belong to 
the regulators of complement activation family of proteins (Fig 2). CFH is a 154 kDa plasma 
protein, soluble glycoprotein that circulates in human plasma at a concentration of 235-810 
μg/ml (Saunders et al, 2006). The family includes the complement regulators CFH and CFH-
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like protein 1 (CFHL1), as well as five CFH-related proteins CFHR1-5 (Jozsi and Zipfel, 
2008). CFHL1 proteins share complement regulatory functions with CFH and interact with 
heparin. The functions of CFH-related proteins (CFHR1 to CFHR5) are not well defined. 
CFHR1, CFHR2 and CFHR4 are constituents of lipoproteins, while CFHR3 is known to 
interact with heparin (Zipfel et al, 2002; Skerka et al, 1997; Hellwage et al, 1999). 
CFH is made up of 20 complement control proteins (CCP) modules. Two major 
functional regions are located at the opposite ends of the protein. The N-terminal four SCR 
domains display complement regulatory activity by facilitating the decay of the C3 convertase 
and acting as a cofactor for factor I. The C-terminus of the protein mediates surface binding 
and target recognition (Oppermann et al, 2006) 
 
Fig. 2 The human complement Factor H gene cluster and structure of the various proteins  
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(a) The human factor H (CFH) gene cluster includes six genes that show a consecutive 
arrangement on human chromosome 1q32. This cluster spans a region of 415 kb and includes 
the CFH and five CFHR genes. For the CFH and the CFHR4 genes, two transcripts have been 
identified, which are derived by alternative splicing and which encode related but distinct 
proteins (CFH and CFHL1, as well as CFHR4A and CFHR4B, respectively). This cluster 
includes homologous repeat regions (marked as A1–C2), which can result in deletion of large 
chromosome fragment due to nonallelic homologous recombination events. Depending on the 
site of recombination as indicated by either the solid or the dotted lines, a large genomic 
deletion is observed in this cluster that either results in a CFH: CFHR1 hybrid gene (solid 
line) or the deletion of CFHR3 and CFHR1 (dotted line). These deletions predispose to 
atypical hemolytic uremic syndrome. (b) The CFH family proteins are plasma glycoproteins, 
being exclusively composed of short consensus repeat (SCR) domains, which are common 
among complement regulatory proteins. The individual SCR domains of the CFHR proteins 
share high sequence identity with each other and also with SCRs of the complement regulator 
CFH. Homologous domains identified by sequence similarity are indicated by vertical 
alignment, and the numbers above each SCR indicate the identity to the corresponding 
domain in CFH at the protein level. All CFHRs contain domains related to the C-terminal 
surface and ligand recognition region (SCRs 19–20) and to the middle region (SCRs 6–9) of 
CFH. CFHR proteins lack SCRs homologous to the complement regulatory domains (SCRs 
1–4) of CFH. The conservation of the N and C termini among the CFHR proteins is indicative 
of related or even overlapping functions. For CFH, the localization of binding domains for 
C3b and its fragments, as well as for heparin and C-reactive protein (CRP), are indicated 
(Jozsi and Zipfel, 2008). 
 
4.2 Function of CFH 
CFH binds to C3b, accelerates the decay of the alternative pathway C3-convertase (C3bBb), 
and acts as a cofactor for the factor I-mediated proteolytic inactivation of C3b (Fig 3) 
(Rodriguez de Cordoba et al, 2004). Evidence supporting the involvement of CFH in 
carcinogenesis is accumulating. For instance, malignant glioblastoma cells produce CFH and 
CFHL-1 (Gasque et al, 1996; Junnikkala et al, 2000). Secretion of soluble complement 
inhibitor CFH and CFHL-1 by ovarian tumor cells could protect tumor cells against humoral 
immune attack and posed an obstacle for therapy with monoclonal antibodies (Junnikkala et 
al, 2002). Similarly, in colon and lung cancer, the possible role of CFH was resistance to 
complement attack (Wilczek et al, 2008; Ajona et al, 2004). Additionally, CFH or related 
  13
proteins were considered as diagnostic markers for transitional cell cancer of the bladder 
(Kinders et al, 1998).  
 
 
Fig. 3 Inactivation of C3b by factor H. Chain structure of the native C3, C3b and iC3b 
molecules. Sites of cleavage by the C3-converstase and factor I in α- and α’-chains of C3 and 
C3b are indicated by arrows. Inactivation of C3b to iC3b by factor I requires the cofactor 
function of factor H. The position of the internal thiolester that establishes the covalent 















AIMS OF THE STUDY 
 
The aims of the study were: 
1. Investigate the expression and binding of CFH in human lung cancer cell lines 
2. Analyze the location of CFH protein in human lung cancer cells 
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The major findings present in the current study can be summarized as follows: 1) CFH was 
expressed in the majority of non-small cell lung cancer cell lines, 2) CFH was not expressed 
in small cell lung cancer cell lines, 3) cancer cells bound CFH to their surface, 4) the majority 
of tumor samples (53.5%) exhibited CFH positive staining, 5) CFH could be a biomarker for 
ADC of lung.  
 
1. Expression of CFH in lung cancer cells 
CFH is known as the most prominent fluid-phase complement inhibitor being present in 
plasma. It performs several activities which ultimately inhibit the alternative complement 
pathway. CFH was expressed in various malignant cell lines including ovarian, colon, bladder, 
liver, and lung cancer cell lines (Wilczek et al, 2008; Junnikkala et al, 2000; Cheng et al, 
2005; Schlaf et al, 2002; Ajona et al, 2007). CFH binds to C3b and acts as a cofactor for the 
factor I-mediated proteolytic inactivation of C3b (Pangburn et al, 1977), while competing 
with factor B in binding to C3b to form the alternative pathway C3-convertase C3bBb 
(Whaley and Ruddy, 1976). It also accelerates the decay of C3bBb. By inhibiting alternative 
complement activity, factor H also protects tumor cells against immune attack (Rodriguez de 
Cordoba et al, 2004; Gasque et al, 1992). Earlier studies showed that, CFH is a marker for 
transitional cell cancer of the bladder (Kinders et al, 1998) and the utility of CFH as a 
diagnostic marker raised the question whether it could be a marker for other malignancies. 
In our study, we analysed the mRNA and protein expression of CFH in a panel of lung 
cancer cell lines by RT-PCR, western blotting, flow cytometry, and immunofluorescence 
analysis. It turned out that several human NSCLC cells constitutively expressed and secreted 
CFH, while in SCLC cells, no CFH expression was detectable. These results are in line with 
previous report by Ajona et al (Ajona et al, 2004), who reported that neither SCLC nor 
carcinoid cell lines expressed CFH, suggesting a phenotypic correlation between the 
expression of CFH and the neuroendocrine differentiation of the tumors. We further analyzed 
the ability of factor H binding to lung cancer cells. It turned out that factor H binding to the 
cell surface is independent on its expression in tumor cells. 
 
2. Expression of CFH in lung tumor tissues 
In the survey of protein expression of CFH in 101 primary lung tumors, we found that more 
than half of the samples (53.5%) showed CFH positive staining, while the other tumor 
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samples were negatively stained, indicating that high expression of CFH is not an infrequent 
feature of this type of cancer. We could only divide the primary tumors into two major 
subgroups of ADC and SCC for statistical analysis, since the sample size of SCLC and LCLC 
was too small to be further evaluated. Although expression of CFH was not significantly 
associated with tumor progression, differentiation, and lymph node metastasis, it was 
significantly higher in ADCs (35/53) than in SCCs (16/41) (p<0.01). So far, the protein 
expression of CFH has only been evaluated in patients with primary colon adenocarcinoma by 
Wilczek et al. They found that CFH was expressed in both primary colon adenocarcinoma and 
metastatic foci in liver (Wilczek et al, 2008). It is not yet clear if overexpression of CFH is a 
common event in adenocarcinoma, nevertheless, the result suggests that CFH could be a novel 
marker to distinguish NSCLC from SCLC and may particularly identify lung 
adenocarcinoma. 
 
3. Clinical usefulness of CFH in human lung cancer 
It has been reported that some human NSCLC cell lines highly expressing CFH or CFH-like 
protein are more susceptible to complement–mediated damage and more efficiently deposited 
C3b on the cell surface when they are blocked by specific anti-factor H antibodies (Ajona et 
al, 2004). Tumor cells that express and bind CFH to their surface can prevent C3b 
accumulation upon their cell membranes leading to resistance of these cells to complement-
mediated lysis (Ajona et al, 2004). Based on these characteristics, we supposed that tumors 
with high expression of CFH could be more aggressive and have a worse clinical outcome.  
To test this hypothesis, we analysed the effect of CFH expression on patient survival. 
Again, in ADC of lung, there was a tendency that CFH positive-tumors had a worse clinical 
outcome compared to CFH negative-tumors, although it did not reach statistical significance. 
Interestingly, patients with ADC who had positive expression of CFH ended with a shorter 
survival time (less than 20 months). Evidence is not sufficient to prove the role of CFH as a 
prognostic marker in ADC of lung. Future studies with more tumor samples are needed to 
warrant the prognostic role of CFH in lung cancer; and we also plan to perform a prospective 
trial to detect the concentration of CFH in blood from lung cancer patients and healthy 
donors, to further investigate the clinical usefulness of CFH in human lung cancer. 
Additionally, in line with the previous observations that CFH binds to apoptotic and 
necrotic cells (Leffler et al, 2010; Mihlan et al, 2009), we found that apoptotic cells expressed 
more CFH compared to non-apoptotic cells of primary lung cancer. Most apoptotic cells do 
not undergo complement-mediated lysis probably due to the overexpression of CFH, which 
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compensates the loss of m-C-Reg, a membrane-bound complement regulatory protein, and 
protect against excessive complement activation and lysis (Trouw et al, 2007).  
Immunotherapy is an attractive approach that, by design, is cancer specific and can 
target disseminated disease with minimal impact on normal tissues (Hirschowitz and Yannelli, 
2009). Immunotherapy is categorized as either passive or active. Passive immunotherapy 
includes any immunological active agent that is made outside the body and does not rely on 
host machinery to function. The most widely applied passive immunotherapies are 
monoclonal antibodies that disrupt tumorigenic cascades by blocking the binding of hormones 
or growth factors to their receptors; examples include cetuximab (Erbitux) and trastuzumab 
(Herceptin), which target epidermal growth factor (EGF) receptors; Gefitinib and Erlotinib, 
which are small molecular tyrosine kinase inhibitors, have directed activity toward EGFR; 
HER-1 and HER-2, respectively, and bevacizumab (Avastin), which interferes with tumor 
angiogenesis by binding to vascular endothelial growth factor (Sandler et al, 2004; Isobe et al, 
2005; Giaccone, 2005; Baselga and Cortes, 2005; Baresi, 2010). By contrast, active 
immunotherapy uses the host’s immune cells and requires an intact immune system to 
function. Active immunotherapy is derived from the knowledge that the immune system can 
discriminate cancer cells from normal cells based on tumor antigen recognition (Abu-Shakra 
et al, 2001; Pardoll, 2003; Raez et al, 2005; Novellino et al, 2005). 
For long, lung cancer was not considered an immune-sensitive malignancy. Although 
there is increasing evidence that NSCLC and SCLC can evoke specific humeral and cellular 
anti-tumor immune responses, lung cancer immunotherapy lags behind similar efforts in 
melanoma, renal cell, and prostate cancer. Our results could provide further insight into the 
understanding of pathogenesis and could have implication for the design of more effective 
immunotherapeutic strategies for this fatal disease. For the next step, we plan to detect the 
concentration of CFH in blood from healthy donors and lung cancer patients (with NSCLC or 
SCLC, before and after chemoradiotherapy), to further investigate the clinical usefulness of 
CFH in human lung cancer. 
In summary, non-small cell lung cancer expressed CFH, and CFH might be a 
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